# OnCo record nct05577702 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05577702/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05577702", "NCT05577702" ;
  schema:name "Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer"@en ;
  schema:description "A phase 2 trial of Alcestobart run by BeiGene, completed."@en ;
  schema:url <https://onco.cc/trials/nct05577702/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05577702> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/alcestobart/> ;
  onco:companies <https://onco.cc/companies/nanjing-leads-biolabs/> .